Tag: UK

Cbis.ob, Cannabis Science Reports Important Validation For Medical Cannabis

blogger /

COLORADO SPRINGS, Colo., (CRWENEWSWIRE) -06/28/10- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, reports an important milestone for the continued validation of medical cannabis, as UK-based GW Pharmaceuticals (http://gwpharm.com/) receives $15 million milestone payment from Bayer. This payment to GW is based on the UK Government’s approval of the “First Prescription Cannabis Medicine”, GW Pharmaceuticals Sativex(R), an “Oromucosal Spray” tincture for the treatment of spasticity due to Multiple Sclerosis (MS). Analysts at Piper Jaffray forecast that peak sales could reach $180 million in Europe and Canada combined. Presently, GW has a market capitalization of over $260 million.

Richard Cowan, Cannabis Science CFO noted, “Bayer’s $15 million ‘milestone payment’ to GW clearly puts the world on notice that pharmaceutical cannabis is now ‘mainstream’. Previously, the US FDA granted GW a Phase III IND for Sativex, and a Phase IIb/III trial for cancer pain is currently ongoing. GW has also received an 18 million dollar licensing fee from Otsuka for the US rights, and they also received millions more from licensing fees from Almiral of Spain for the European rights outside of the UK. The licensees also pay for the work necessary for regulatory approval. Clearly, Big Pharma recognizes the explosive growth this industry is experiencing and does not want to be left behind. Obviously, licensing of products and territories — which is common for new biotech companies — suggests another important way Cannabis Science can move forward with its financing objectives.”

Dr. Robert Melamede, PhD., Cannabis Science President and CEO, said, “The UK Government’s approval of Sativex(R) is long overdue. MS patients in the UK and around the world have long used cannabis to get relief from pain and spasticity. We hope, given this recognition of the medical value of cannabis, that the UK government will stop arresting patients who use the plant to deal with their pain and suffering, whatever their medical problems may be. Also, we think this approval should lead to faster regulatory action in the future for medicines derived from whole plant extracts from cannabis. Given the millennia of use that proves the safety of cannabis, and its widespread medical use by millions of people for a great variety of problems today, we hope that the approval of Sativex(R) will lead to the fast-tracking of other whole cannabis extracts by the regulatory authorities.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:

Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888

www.cannabisscience.com
Investor Relations
Mark J. Friedman
1.877.431.CBIS (2247)

www.cannabisscience.com

***********************************

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
***********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdi

The Art and Science of CV Writing

blogger /

Most people would scoff at the title of this article -The Art and Science of CV Writing,’ because to most people it isn’t an art form and there isn’t much science at all when it comes to writing a CV. For many it is simply a matter of following the age-old set of rules, or filling in the blanks on a template. /p>

The trouble with this attitude is that it is somewhat naive as well as outdated, and although for the vast majority, the art and science of CV writing has stood still for decades, for some at least, it has moved on. And I detail some of the very latest developments and revelations in my forthcoming CV book.

You should be aware that just because most people write CVs in the same laissez-faire haphazard manner, it doesn’t mean to say that everyone else does. Indeed, the very best CV writers (who are few and far between) apply real science and methodology in their work; amongst other things drawing upon psychology to attract the employer as well as sales and marketing techniques to pinpoint and hammer home the right message. All this is far easier said than done, and takes more than just methods, but writing talent, originality and creativity.

CV writing in the 21st century really is an art and science in itself.

Of course, most people are still using 20th-century techniques, and it is not impossible to get jobs with an old school CV, or even one which isn’t as powerful as it could be. However, the thing you should remember is that just because there is still a chance of landing good jobs with an unspectacular CV, it doesn’t necessarily mean that it is best to apply with one. It isn’t. After all, the job market is extremely competitive these days, you need to stand out from the crowd, and you need to present your case in the most powerful terms. And the prospect of doing this with a conventional CV is becoming ever harder. If you want a brighter career future then rather than looking backwards you really need a more futuristic CV. I’m not talking about a -beam me up Scotty’ neon light sabre of a CV – just something professional looking, but very hard-hitting and highly effective once it falls in the lap of an employer.

If you listen to most CV companies they will almost all tell you they can write just that. However, since the vast majority of CV companies use outdated methods, it is highly unlikely they can. So just beware of that when you are contemplating who you want to help you with your CV.

Author biography Paul Hichens is highly respected UK based CV writer, his radical CV book is due for publication in the summer of 2013 .